PubMed:19891556 / 448-758 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"6780","span":{"begin":73,"end":80},"obj":"GeneOrGeneProduct"},{"id":"6781","span":{"begin":158,"end":169},"obj":"ChemicalEntity"}],"attributes":[{"id":"A8","pred":"db_id","subj":"6780","obj":"NCBIGene:1557"},{"id":"A9","pred":"db_id","subj":"6781","obj":"MESH:D000077144"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}

{"project":"LitCoin-sentences","denotations":[{"id":"T5","span":{"begin":0,"end":310},"obj":"Sentence"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T5","span":{"begin":73,"end":80},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":96,"end":104},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":179,"end":185},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":218,"end":228},"obj":"GeneOrGeneProduct"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T2","span":{"begin":73,"end":80},"obj":"GeneOrGeneProduct"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T2","span":{"begin":73,"end":80},"obj":"GeneOrGeneProduct"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T10","span":{"begin":158,"end":169},"obj":"ChemicalEntity"}],"attributes":[{"id":"A10","pred":"ID:","subj":"T10","obj":"D000077144"},{"id":"A11","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A12","pred":"ID:","subj":"T10","obj":"ChemicalEntity"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T10","span":{"begin":158,"end":169},"obj":"ChemicalEntity"},{"id":"T2","span":{"begin":73,"end":80},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A12","pred":"ID:","subj":"T10","obj":"ChemicalEntity"},{"id":"A11","pred":"ID:","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A10","pred":"ID:","subj":"T10","obj":"D000077144"}],"text":"Several studies have reported that, compared with wild-type individuals, CYP2C19 variant allele carriers exhibit a significantly lower capacity to metabolize clopidogrel into its active metabolite and inhibit platelet activation, and are therefore at significantly higher risk of adverse cardiovascular events."}